Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus

Journal of Clinical Rheumatology

Volumn 22, Issue 6, 2016, Pages 320-323

  Bermea, Rene S ^a   Sharma, Niharika ^b   Cohen, Kenneth ^c   Liarski, Vladimir M ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

eculizumab; hemolytic uremic syndrome; SLE; thrombotic microangiopathy

Indexed keywords

CYCLOPHOSPHAMIDE; ECULIZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ADOLESCENT; ADULT; ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BLOODY DIARRHEA; CASE REPORT; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEMOPTYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; LEG SWELLING; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALAISE; MALE; NAUSEA; OLIGURIA; PATIENT COMPLIANCE; PLASMA EXCHANGE; PRIORITY JOURNAL; REFRACTORY THROMBOCYTOPENIA; RESPIRATORY DISTRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; VOMITING; ACUTE KIDNEY INJURY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLICATION; PATHOPHYSIOLOGY; PROCEDURES; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PLATELET COUNT; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84986207697     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000423     Document Type: Article

References (14)

1. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl JMed. 2014;371:654-666.
2. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
3. Bao L, Quigg RJ. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol. 2007;27:69-80.
4. Wang Y, Hu Q, Madri JA, et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A. 1996;93:8563-8568.
5. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2015;65:127-130.
6. Coppo R, Peruzzi L, Amore A, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol Berl Ger. 2015;30:167-172.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
8. D?Agati VD, Weening JJ, Schwartz MM, et al. The Classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250.
9. Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983;75: 382-391.
10. D?Cruz D, Houssiau FA, Vasconcelos C, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
11. Moake JL. Thrombotic microangiopathies. N Engl JMed. 2002;347: 589-600.
12. Walport MJ. Complement. First of two parts. N Engl JMed. 2001;344: 1058-1066.
13. Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125:1526-1531.
14. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Car Res. 2012;64:797-808.